GlassScriptPhysician profile
Marc William Cromie
NPI 1083683668
$105,791.97
in general payments reported to CMS, 2019-2025
47 companies · $31K in 2025
The $31K reported for 2025 was more than what 94% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $5,112 · 2021: $7,746 · 2022: $5,865 · 2023: $11K · 2024: $33K · 2025: $31K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $61K · Food and Beverage: $11K · Consulting Fee: $2,292 · Travel and Lodging: $930 · Education: $86.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $60,795.00 |
| Food and Beverage | $11,429.17 |
| Consulting Fee | $2,292.00 |
| Travel and Lodging | $929.57 |
| Education | $86.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $84,437.25 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $2,550.91 | 2019-2025 | Dupixent |
| Regeneron Pharmaceuticals, INC. | $2,292.00 | 2025 | Dupixent |
| Pharming Healthcare, INC. | $2,212.58 | 2020-2025 | Ruconest |
| Glaxosmithkline, LLC. | $1,958.00 | 2019-2024 | Nucala, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $1,851.50 | 2019-2025 | |
| Csl Behring | $1,414.38 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Alk-Abello, INC | $1,410.20 | 2021-2023 | Odactra, Ragwitek, Grastek |
| Amgen INC. | $906.70 | 2021-2025 | Tezspire |
| Genzyme Corporation | $879.72 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $721.46 | 2020-2025 | Hyqvia, Cuvitru, Takhzyro |
| Octapharma USA, INC. | $618.94 | 2021-2025 | Cutaquig |
| Genentech USA, INC. | $585.17 | 2019-2025 | Xolair |
| Grifols USA, LLC | $527.14 | 2020-2025 | Prolastin-C Liquid, Xembify |
| Biocryst US Sales Co., LLC | $430.61 | 2021-2025 | Orladeyo |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Cromie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.